Skip to main content
IKT logo

IKT · Inhibikase Therapeutics, Inc. · Earnings Calls, Transcripts & Webcasts

Track IKT — free
$1.32 +0.02 (+1.54%) At close · Nov 20 Q2 2024 earnings call transcript
Market Cap
$185.16M
Shares
140.27M
Volume · Nov 20 1.11M Avg daily vol (3M) 580.26K

Inhibikase Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Inhibikase Therapeutics, Inc. (IKT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-02
Inhibikase Therapeutics, Inc. (IKT) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-16
Inhibikase Therapeutics, Inc. (IKT) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-10
Inhibikase Therapeutics, Inc. (IKT) Q3 2026 Earnings Call
Net interest income
$1.76M
▲ 110.2% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-11
Inhibikase Therapeutics, Inc. (IKT) Q2 2026 Earnings Call
Revenue
$0
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Inhibikase Therapeutics, Inc. (IKT) Q1 2026 Earnings Call
Revenue
$0
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Inhibikase Therapeutics, Inc. (IKT) Q4 2025 Earnings Call
Net interest income
$1.04M*
▲ 30.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Inhibikase Therapeutics, Inc. (IKT) Q3 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Inhibikase Therapeutics, Inc. (IKT) Q2 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Inhibikase Therapeutics, Inc. (IKT) Q1 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inhibikase Therapeutics, Inc. (IKT) Q4 2024 Earnings Call
Revenue
$0*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Positive tone IkT-001Pro in pulmonary arterial hypertension Cash position and capital needs Biomarker and diagnostic tools
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
Confident tone Pulmonary Arterial Hypertension (PAH) Opportunity Alpha-Synuclein Biomarker and Antibody Development Capital Needs and Financing Constraints
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Revenue
$1*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call Transcript
Revenue
$79,569
▲ 991.3% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
Revenue
$116,410
▲ 1676.7% YoY
Diluted EPS
$-1.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript
Revenue
$64,521
▲ 40.2% YoY
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Call Transcript
Revenue
$63,566*
▲ 3169.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-17
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
Revenue
$7,291
▼ 97.8% YoY
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q2 2022 Earnings Call Transcript
Revenue
$6,552
▼ 99.5% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q1 2022 Earnings Call Transcript
Revenue
$46,031
▼ 96.7% YoY
Diluted EPS
$-1.08
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Inhibikase Therapeutics, Inc. (IKT) Q4 2021 Earnings Call Transcript
Revenue
$1,944*
▼ 98.9% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q4
2021-04-01
Inhibikase Therapeutics, Inc. (IKT) Q4 2020 Earnings Call
Revenue
$170,416*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–22 of 22 webcasts
Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 109 filings 103 filers Visit website Investor relations